1: News and Updates in Diabetes Care from February 2025

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss the changing landscape of GLP-1 receptor agonist-based therapies in light of Eli Lilly and Company’s announcement of new tirzepatide (Zepbound) single-dose vials and reduced pricing as well as the FDA decision to remove semaglutide from the drug shortage list. Later in the episode, hosts focus on updates in diabetes technology from the month of February, with a particular focus on the FDA’s historic clearance of the Tandem Control-IQ automated insulin delivery (AID) for type 2 diabetes.

There are no comments yet.

Please log in to write the first comment.